独家专报！00后唱作人钱正昊全新单曲《月光化石 Moon Fossil》上线 温暖治愈 唱响自我认知

00后唱作人钱正昊全新单曲《月光化石 Moon Fossil》上线 温暖治愈 唱响自我认知

2024年1月5日，00后新生代唱作人钱正昊全新单曲《月光化石 Moon Fossil》正式上线，这也是钱正昊学成归国后发布的首支新歌。该歌曲由钱正昊包揽词曲创作和编曲制作，融汇了超流行、极简、实验电子、雷鬼盾等多元音乐元素，通过超现实的幻想表达自我认知的解构与重建，呈现出丰富而多元的音乐景观。

钱正昊，曾作为《偶像练习生》中的人气选手、《歌手》中年龄最小的踢馆选手而备受关注。近年来，钱正昊潜心学习音乐，不断提升自己的创作实力。此次推出的新单曲《月光化石 Moon Fossil》，是他对音乐全新的一次探索和尝试。

歌曲《月光化石 Moon Fossil》以独特的视角审视自我，将内心世界具象化为“月光化石”，寄托了钱正昊对自我认知的思考和感悟。歌词中唱道：“越过迷雾 找到真相 才能看见 闪耀的光芒”，传达了积极向上的力量，鼓励人们直面内心，勇敢追寻梦想。

钱正昊表示，这首歌的创作灵感来源于他留学期间的感悟。在异乡独自打拼的日子里，他曾经历过迷茫和彷徨，也收获了成长和蜕变。歌曲中所表达的情感，正是他这段经历的真实写照。

《月光化石 Moon Fossil》的上线，不仅标志着钱正昊音乐风格的全新突破，也展现了他深厚的音乐功底和创作才华。相信这首歌曲一定会引起听众的共鸣，在音乐世界中留下属于自己的印记。

钱正昊简介

钱正昊，00后新生代唱作人，出生于四川成都。2018年，参加爱奇艺偶像竞演养成类节目《偶像练习生》，获得22强。2019年，参加湖南卫视音乐竞技节目《歌手》，成为节目历史上年龄最小的踢馆选手。同年，发行首支个人单曲《少年》。2020年，发行首张个人EP《棱镜》。2021年，发行第二张个人EP《蜉蝣》。

歌曲信息

歌曲名称：《月光化石 Moon Fossil》

演唱者：钱正昊

词曲创作：钱正昊

编曲制作：钱正昊

发行时间：2024年1月5日

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.